Baxter bids $3,800 million for WR Grace's renal business
This article was originally published in Clinica
Baxter has offered $3,800 million in cash and stock to take over WR Grace's dialysis subsidiary National Medical Care (NMC). Baxter made its offer on January 31st in a letter to Grace's CEO, Albert Costello, with a request to respond within 24 hours. However, Grace has not indicated any willingness to enter into discussions, Baxter said when it went public with the offer on February 2nd. At the time Clinica went to press, no comment from Grace was available.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.